scholarly article | Q13442814 |
P2093 | author name string | Chao Cheng | |
Fang Wang | |||
Xu Zhang | |||
Li-wu Fu | |||
Xiao-kun Wang | |||
Yong-ju Liang | |||
Hong-bing Huang | |||
Wang Zhou | |||
Wen-jing Zhou | |||
Kenneth Kin Wah To | |||
P2860 | cites work | Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol | Q40036920 |
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance | Q40050525 | ||
Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo | Q40345597 | ||
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. | Q40410062 | ||
Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. | Q40530013 | ||
Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. | Q40561425 | ||
Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. | Q40904151 | ||
Gender specific drug metabolism of PF-02341066 in rats--role of sulfoconjugation | Q43072077 | ||
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. | Q43739398 | ||
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. | Q44183117 | ||
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. | Q44373949 | ||
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. | Q44450066 | ||
Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance | Q44687014 | ||
Screening novel, potent multidrug-resistant modulators from imidazole derivatives | Q45011364 | ||
Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors | Q84966132 | ||
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance | Q24645668 | ||
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer | Q27851410 | ||
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma | Q27851421 | ||
Cell signaling by receptor tyrosine kinases | Q27860474 | ||
Oncogenic kinase signalling | Q28189493 | ||
The human ATP-binding cassette (ABC) transporter superfamily | Q28204495 | ||
Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function | Q28475378 | ||
Tumour stem cells and drug resistance | Q29617742 | ||
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) | Q33194199 | ||
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers | Q33235069 | ||
Anthracenedione derivative 1403P-3 induces apoptosis in KB and KBv200 cells via reactive oxygen species-independent mitochondrial pathway and death receptor pathway | Q33296974 | ||
An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis | Q33588267 | ||
Biochemical, cellular, and pharmacological aspects of the multidrug transporter | Q33636699 | ||
The human ATP-binding cassette (ABC) transporter superfamily. | Q34083168 | ||
Guide to Receptors and Channels (GRAC), 5th edition | Q34228968 | ||
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms | Q34625881 | ||
Smart drugs: tyrosine kinase inhibitors in cancer therapy | Q34710595 | ||
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). | Q34743441 | ||
Activation of the PI3K/Akt pathway and chemotherapeutic resistance | Q35046899 | ||
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. | Q35048738 | ||
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins | Q35924859 | ||
Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. | Q36125609 | ||
Targeting HER1/EGFR in cancer therapy: experience with erlotinib | Q36429516 | ||
Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 | ||
HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy | Q36593180 | ||
Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). | Q36691571 | ||
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib | Q37000538 | ||
Genomics and the mechanism of P-glycoprotein (ABCB1). | Q37023913 | ||
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 | Q37119716 | ||
Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? | Q37853578 | ||
ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance | Q38510908 | ||
Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer | Q39574492 | ||
Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function | Q39877772 | ||
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. | Q39881351 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | multiple drug resistance | Q643839 |
crizotinib | Q5186964 | ||
P304 | page(s) | 1669-1683 | |
P577 | publication date | 2012-07-01 | |
P1433 | published in | British Journal of Pharmacology | Q919631 |
P1476 | title | Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein | |
P478 | volume | 166 |
Q64054594 | A hypercoagulable state leading to venous limb gangrene associated with occult lung adenocarcinoma |
Q28541630 | A new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cells |
Q35171274 | ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors |
Q37739472 | Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo |
Q45404446 | Apoptosis sensitization by Euphorbia factor L1 in ABCB1-mediated multidrug resistant K562/ADR cells. |
Q89145785 | Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer |
Q39016059 | Co-delivery of Sildenafil (Viagra(®)) and Crizotinib for synergistic and improved anti-tumoral therapy. |
Q58097458 | Comparative Gene Expression Analysis in WM164 Melanoma Cells Revealed That --Dimethylacrylshikonin Leads to ROS Generation, Loss of Mitochondrial Membrane Potential, and Autophagy Induction |
Q39416426 | Crizotinib for the treatment of non-small-cell lung cancer |
Q42373819 | Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents |
Q49843204 | Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo |
Q36212765 | Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway |
Q37707577 | Degradation of P-glycoprotein by pristimerin contributes to overcoming ABCB1-mediated chemotherapeutic drug resistance in vitro |
Q28069761 | Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter? |
Q38859977 | Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. |
Q36689070 | Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo |
Q47100454 | Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates |
Q38847914 | Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer |
Q35633633 | Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma. |
Q35860275 | Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice |
Q46041746 | Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar |
Q28553930 | Integrating Domain Specific Knowledge and Network Analysis to Predict Drug Sensitivity of Cancer Cell Lines |
Q51069180 | Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3. |
Q37697125 | Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis |
Q96304650 | Low-Dose Crizotinib, a Tyrosine Kinase Inhibitor, Highly and Specifically Sensitizes P-Glycoprotein-Overexpressing Chemoresistant Cancer Cells Through Induction of Late Apoptosis in vivo and in vitro |
Q39202090 | Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein |
Q38718947 | Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib |
Q35978108 | Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer |
Q38242601 | Pharmacogenetics of membrane transporters: a review of current approaches. |
Q39031326 | Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy. |
Q38366828 | Pharmacokinetics of crizotinib in NSCLC patients. |
Q38984689 | Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma |
Q33751197 | Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells |
Q90347564 | Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells |
Q90274971 | Reversal of ABCB1-related multidrug resistance by ERK5-IN-1 |
Q96304537 | Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo |
Q51572037 | Synergism between ivermectin and the tyrosine kinase/P-glycoprotein inhibitor crizotinib against Haemonchus contortus larvae in vitro. |
Q58097468 | Synthesis of Novel Shikonin Derivatives and Pharmacological Effects of Cyclopropylacetylshikonin on Melanoma Cells |
Q36887730 | The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines |
Q35016736 | Transgenic plants as low-cost platform for chemotherapeutic drugs screening |
Q36709217 | Tubulin-targeting agent combination therapies: dosing schedule could matter |
Q49888021 | Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. |